The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

Amos Kirilovsky, Carine El Sissy, Guy Zeitoun, Florence Marliot, Nacilla Haicheur, Christine Lagorce-Pagès, Julien Taieb, Mehdi Karoui, Petra Custers, Edina Dizdarevic, Soledad Iseas, Torben Frøstrup Hansen, Lars Henrik Jensen, Geerard L. Beets, Jean Pierre Gérard, Mireia Castillo-Martin, Nuno L. Figueiredo, Angelita Habr-Gama, Rodrigo O. Perez, Jérôme GalonFranck Pagès*


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

16 Downloads (Pure)


Because of the function and anatomical environment of the rectum, therapeutic strategies for local advanced rectal cancer (LARC) must deal with two challenging stressors that are a high-risk of local and distal recurrences and a high-risk of poor quality of life (QoL). Over the last three decades, advances in screening tests, therapies, and combined-modality treatment options and strategies have improved the prognosis of patients with LARC. However, owing to the heterogeneous nature of LARC and genetic status, the patient may not respond to a specific therapy and may be at increased risk of side-effects without the life-prolonging benefit. Indeed, each therapy can cause its own side-effects, which may worsen by a combination of treatments resulting in long-term poor QoL. In LARC, QoL has become even more essential with the increasing incidence of rectal cancer in young individuals. Herein, we analyzed the value of the Immunoscore-Biopsy (performed on tumor biopsy at diagnosis) in predicting outcomes, alone or in association with clinical and imaging data, for each therapy used in LARC.
Sider (fra-til)18-31
StatusUdgivet - 2022


Dyk ned i forskningsemnerne om 'The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?'. Sammen danner de et unikt fingeraftryk.